ScripOnce seen as the next big thing in cancer, cytokine-based therapies lost their shine after numerous trial flops, but Synthekine is among a number of companies that believe they can succeed with a ne
ScripA combination product containing Merck & Co., Inc. ’s Keytruda plus its investigational anti-TIGIT therapy, vibostolimab, has missed the mark in a Phase II lung cancer trial, adding to a spate of dis
ScripReal world data has been gaining credence among regulators for decisions on drug approval and label expansion given that randomized clinical trials take place in controlled environments in a well-defi